PDE4
ACTIVE_COMPETITORS 1 Asset
CLINICAL_EXPERIMENTS 8 Live Trials
BIOCLASS THERAPEUTIC_AREA
[01_MECHANISTIC_DESCRIPTIVE_NARRATIVE]
No supplemental biological data description cataloged.
[02_MACROMOLECULAR_3D_CONFORMATION]
Interactive structural projection resolved from the AlphaFold database engine configuration dataset mapping.
PDE4
UNIPROT: Q86V67
ALPHAFOLD_3D_PREDICTION
INITIALIZING_STRUCTURAL_BIOMATRIX...
[03_ACTIVE_COMPETITIVE_LANDSCAPE]
THERAPEUTIC ASSET
ALIAS
MAX PHASE
SPONSORING ISSUER / CORPORATION
[04_CROSS_REFERENCED_CLINICAL_EXPERIMENTS]
REGISTRY ID
EXPERIMENT TITLE
STAGE
EVALUATED ASSET
STATUS
NCT02187250 ↗
PDE-4 Inhibitor Roflumilast and GLP-1 Agonist Liraglutide in Polycystic Ovary Syndrome
P-4
ARQ-151
completed
NCT01664624 ↗
Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes
P-1
ARQ-151
completed
NCT00242294 ↗
Efficacy and Safety of Roflumilast in Japanese Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (APTA-2217-06)
P-2
ARQ-151
completed
NCT04108377 ↗
Phosphodiesterase 4 Inhibitor, Roflumilast, and the Effects of Inhibition in Severe Asthma
P-1
ARQ-151
terminated
NCT04211389 ↗
Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
P-3
ARQ-151
completed
NCT04800172 ↗
The Possible Effects of Roflumilast on Obesity Related Disorders
P-3
ARQ-151
completed
NCT04973228 ↗
Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)
P-3
ARQ-151
completed
NCT00163527 ↗
Efficacy and Safety of Oral Roflumilast Taken With Low Dose Inhaled Corticosteroids in Patients With Asthma (12 to 70 y) (BY217/M2-013)
P-3
ARQ-151
completed